Skip to content

Effect of TENS on Sensory Parameters in Diabetic Polyneuropathy

The Effect of Transcutaneous Electrical Nerve Stimulation on Sensory Parameters in Patients With Diabetic Polyneuropathy: A Randomized, Double-Blind, Sham-Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07807748
Enrollment
30
Registered
2026-09-08
Start date
2021-09-06
Completion date
2021-11-01
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathies, Diabetic Neuropathy, Painful, Peripheral Nervous System Diseases

Brief summary

Diabetic polyneuropathy is a common complication of diabetes that damages the nerves of the feet and legs. Besides causing pain, it gradually reduces the ability to feel light touch on the sole of the foot. This loss of protective sensation is important because it removes the warning signal that normally prevents unnoticed injuries, which can lead to foot ulcers. Transcutaneous electrical nerve stimulation (TENS) is a non-drug treatment that delivers mild electrical currents through the skin using surface electrodes. It is inexpensive, widely available, and generally well tolerated. Most previous studies of TENS in diabetic polyneuropathy have looked at whether it relieves pain. Far less is known about whether it affects touch sensation, and whether the frequency of the stimulation matters. This study compares three groups of patients with long-standing diabetic polyneuropathy. One group receives high-frequency TENS (100 Hz), one receives low-frequency TENS (5 Hz), and one receives sham stimulation at an intensity too low to have a treatment effect. Treatment is given five days a week for eight weeks, with electrodes placed on the calf and the sole of the foot. The main measure is the lightest touch a participant can feel on the big toe, tested with Semmes-Weinstein monofilaments before and after the eight-week period. Additional measures include electrical and pressure pain thresholds and questionnaires on pain, mood, and quality of life. Participants and the researchers performing the assessments do not know which group each participant is in.

Detailed description

BACKGROUND AND RATIONALE Distal symmetric polyneuropathy is the most common chronic complication of diabetes and the principal cause of the sensory loss that precedes foot ulceration. Current management is directed almost entirely at symptomatic control of neuropathic pain and is not expected to modify sensory function. Transcutaneous electrical nerve stimulation (TENS) has been studied in this population, but trials have used pain intensity or composite symptom scores as endpoints, and cutaneous sensory function has rarely been treated as a prespecified outcome. Stimulation frequency provides a mechanistic rationale for outcomes that may differ in kind. Conventional high-frequency, sensory-intensity TENS preferentially recruits large-diameter, low-threshold A-beta afferents, whereas low-frequency, higher-intensity stimulation is generally attributed to endogenous opioid-mediated descending inhibition. The A-beta population engaged by the former is the same population that mediates detection of weak mechanical stimuli and that monofilament testing assesses. Converging evidence from the repetitive sensory stimulation literature indicates that prolonged, passive peripheral input can lower tactile thresholds through long-term-potentiation-like mechanisms, with a frequency dependence paralleling the induction of synaptic potentiation and depression. DESIGN Single-centre, randomised, double-blind, sham-controlled, parallel-group trial with three arms allocated in a 1:1:1 ratio. Participants were recruited from the Endocrinology and Metabolism outpatient clinic of Akdeniz University Faculty of Medicine; assessments were performed at the Akdeniz University Sports Sciences Research and Application Centre. ALLOCATION AND BLINDING Allocation was performed by a lot-drawing procedure after written informed consent and before baseline assessment. Simple randomisation was used, without blocking or stratification. Participants and outcome assessors were blinded to group assignment. The sham arm followed an identical procedure at a sub-therapeutic intensity, so participants were unaware of whether they received active or sham stimulation. All sensory, nociceptive, and questionnaire-based assessments were performed by evaluators blinded to allocation. INTERVENTIONS TENS was delivered with a dual-channel PRIMERA TENS/NMES stimulator (DJO, LLC, USA) using standard 2-inch self-adhesive electrodes, one placed on the calf and one on the plantar surface of the foot. A zero-direct-current, asymmetric biphasic rectangular waveform was used. Intensity was individually adjusted to each participant's sensory tolerance and maintained at a comfortable level throughout each session. Sessions were delivered five days per week for eight weeks in all arms. ASSESSMENTS Assessments were performed at baseline and repeated in the week following the eight-week programme. The primary outcome was the tactile detection threshold at the plantar surface of the great toe, measured with Semmes-Weinstein monofilaments (index 1.65-6.65), with the corresponding buckling force recorded in grams; a higher value indicates a more impaired threshold. All monofilament measurements were obtained by a single blinded investigator. Secondary outcomes were exploratory and comprised electrical pain detection and tolerance thresholds obtained by transcutaneous sural nerve stimulation using an ascending method of limits; the nociceptive flexion reflex recorded by surface electromyography from the short head of the biceps femoris; pressure pain threshold and tolerance measured by digital algometry at the dominant forearm and leg; and patient-reported measures of neuropathic pain, pain quality, depressive symptoms, and quality of life. STATISTICAL APPROACH Non-parametric methods were planned throughout because of small, unequal group sizes and the expected right-skew of several sensory variables. Continuous variables are summarised as median with interquartile range. Within-group change was tested with the Wilcoxon signed-rank test and between-group differences at post-treatment with the Kruskal-Wallis test, followed for the primary outcome by prespecified Mann-Whitney contrasts of each active arm against sham. Benjamini-Hochberg false-discovery-rate correction was applied across the exploratory secondary family.

Interventions

DEVICEHigh-Frequency TENS

Transcutaneous electrical nerve stimulation delivered with a dual-channel PRIMERA TENS/NMES stimulator (DJO, LLC, USA) using standard 2-inch self-adhesive electrodes, one placed on the calf and one on the plantar surface of the foot. Stimulation was delivered at 100 Hz with a pulse width of 200 microseconds for 30 minutes per session, using a zero-direct-current, asymmetric biphasic rectangular waveform. Intensity was individually adjusted to each participant's sensory tolerance. Sessions were delivered five days per week for eight weeks.

DEVICELow-Frequency TENS

Transcutaneous electrical nerve stimulation delivered with the same device, electrode type, and electrode placement as the high-frequency arm. Stimulation was delivered at 5 Hz with a pulse width of 175 microseconds for 15 minutes per session, using a zero-direct-current, asymmetric biphasic rectangular waveform. Intensity was individually adjusted to each participant's sensory tolerance. Sessions were delivered five days per week for eight weeks.

DEVICESham TENS

Sham stimulation delivered with the same device, electrode type, and electrode placement as the active arms, at a sub-therapeutic intensity (approximately 2-3 mA) insufficient to produce a physiological effect. All other aspects of the procedure were identical to the low-frequency arm, including session duration and schedule. Sessions were delivered five days per week for eight weeks.

Sponsors

Burdur Mehmet Akif Ersoy University
Lead SponsorOTHER
Akdeniz University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 1 or type 2 diabetes mellitus * Clinically confirmed diabetic peripheral polyneuropathy of at least five years' duration, diagnosed by an endocrinologist during routine outpatient follow-up on the basis of distal symmetric sensory symptoms together with abnormal bedside sensory testing * Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score of 9 or above * Standardized Mini-Mental State Examination score above 24 * Glycated haemoglobin (HbA1c) below 8.5% * Wagner grade 0 feet (intact plantar skin without ulceration) * Willing to continue prescribed diet and hypoglycaemic treatment unchanged throughout the study

Exclusion criteria

* Use of a cardiac pacemaker * Alcohol dependence * Peripheral arterial disease * Renal failure * Hepatic failure * Hypothyroidism * Vitamin B12 deficiency * Folate deficiency * Sarcoidosis * Active infection * Malignancy * Coagulopathy * Skin lesion, discolouration, or allergic reaction at the electrode sites

Design outcomes

Primary

MeasureTime frameDescription
Tactile detection threshold at the plantar great toeBaseline and within one week after the end of the eight-week intervention periodCutaneous touch sensation assessed with Semmes-Weinstein monofilaments (index 1.65-6.65) applied to the plantar surface of the right great toe, with the corresponding buckling force recorded in grams. A higher value indicates a more impaired (less sensitive) threshold. All measurements were obtained by a single investigator blinded to group allocation.

Secondary

MeasureTime frameDescription
Electrical pain detection threshold (ePDT)Baseline and within one week after the end of the eight-week intervention periodLowest current at which a transcutaneous electrical stimulus applied over the retromalleolar course of the sural nerve was first reported as painful, recorded in milliamperes. Stimuli consisted of trains of six 1-ms rectangular pulses at 250 Hz; current was increased from 1 mA in 1-mA steps using an ascending method of limits.
Electrical pain tolerance threshold (ePTT)Baseline and within one week after the end of the eight-week intervention periodHighest current the participant was willing to accept during ascending transcutaneous sural nerve stimulation, recorded in milliamperes. At tolerance, participants rated perceived stimulus intensity on a 0-10 sensory analogue scale.
Nociceptive flexion reflex (RIII) thresholdBaseline and within one week after the end of the eight-week intervention periodThreshold for the nociceptive flexion reflex, assessed by surface electromyography from the short head of the ipsilateral biceps femoris during ascending transcutaneous sural nerve stimulation, recorded in milliamperes.
Pressure pain threshold (PPT)Baseline and within one week after the end of the eight-week intervention periodLoad at which pressure applied by a digital algometer with a 1 cm2 application surface at a rate of 1 kg/s was first perceived as painful, recorded in kilograms, from flexor and extensor muscle and myofascial regions of the dominant forearm and leg. Each site was measured twice and the lowest value recorded.
Pressure pain tolerance threshold (PPTO)Baseline and within one week after the end of the eight-week intervention periodLoad at which pressure applied by digital algometry could no longer be tolerated, recorded in kilograms, from the same sites as the pressure pain threshold. Each site was measured twice and the highest value recorded.
Neuropathic pain score (LANSS)Baseline and within one week after the end of the eight-week intervention periodLeeds Assessment of Neuropathic Symptoms and Signs, a validated scale combining self-reported sensory descriptors with bedside sensory testing. Scores range from 0 to 24; a score of 12 or above indicates pain of predominantly neuropathic origin.
Pain quality (McGill Pain Questionnaire)Baseline and within one week after the end of the eight-week intervention periodMcGill-Melzack Pain Questionnaire, assessing sensory, affective, and evaluative dimensions of pain experience.
Depressive symptoms (Beck Depression Inventory)Baseline and within one week after the end of the eight-week intervention periodModified Beck Depression Inventory, a self-report measure of depressive symptom severity.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026